PURPOSE: To determine whether radiation therapy (RT) of patients with Wilms tumor of favorable histology prevented flank recurrence and thereby improved the survival outcomes. METHODS AND MATERIALS: Recurrence and mortality risks were compared among groups of patients with Stage I-IV/favorable histology Wilms tumor enrolled in the third (n = 1,640) and fourth (n = 2,066) National Wilms Tumor Study Group studies. RESULTS: Proportions of patients with flank recurrence were 0 of 513 = 0.0% for 20 Gy, 12 of 805 = 1.5% for 10 Gy, and 44 of 2,388 = 1.8% for no flank RT (p trend = 0.001 adjusted for stage and doxorubicin); for intra-abdominal (including flank) recurrence they were 5 of 513 = 1.0%, 30 of 805 = 3.7%, and 58 of 2,388 = 2.4%, respectively (p trend = 0.02 adjusted). Survival percentages at 8 years after intra-abdominal recurrence were 0 of 5 = 0% for 20 Gy, 10 of 30 = 33% for 10 Gy, and 34 of 58 = 56% for no RT (p trend = 0.0001). NWTS-4 discontinued use of 20 Gy RT, and the 8-year flank recurrence risk increased to 2.1% from 1.0% on NWTS-3 (p = 0.013). However, event-free survival was unaltered (88% vs. 86%, p = 0.39), and overall survival was better (93.8% vs. 90.8%, p = 0.036) on NWTS-4. CONCLUSIONS: Partly because of lower postrecurrence mortality among nonirradiated patients, prevention of flank recurrence by RT did not improve survival. It is important to evaluate entire treatment policies with regard to long-term outcomes.
PURPOSE: To determine whether radiation therapy (RT) of patients with Wilms tumor of favorable histology prevented flank recurrence and thereby improved the survival outcomes. METHODS AND MATERIALS: Recurrence and mortality risks were compared among groups of patients with Stage I-IV/favorable histology Wilms tumor enrolled in the third (n = 1,640) and fourth (n = 2,066) National Wilms Tumor Study Group studies. RESULTS: Proportions of patients with flank recurrence were 0 of 513 = 0.0% for 20 Gy, 12 of 805 = 1.5% for 10 Gy, and 44 of 2,388 = 1.8% for no flank RT (p trend = 0.001 adjusted for stage and doxorubicin); for intra-abdominal (including flank) recurrence they were 5 of 513 = 1.0%, 30 of 805 = 3.7%, and 58 of 2,388 = 2.4%, respectively (p trend = 0.02 adjusted). Survival percentages at 8 years after intra-abdominal recurrence were 0 of 5 = 0% for 20 Gy, 10 of 30 = 33% for 10 Gy, and 34 of 58 = 56% for no RT (p trend = 0.0001). NWTS-4 discontinued use of 20 Gy RT, and the 8-year flank recurrence risk increased to 2.1% from 1.0% on NWTS-3 (p = 0.013). However, event-free survival was unaltered (88% vs. 86%, p = 0.39), and overall survival was better (93.8% vs. 90.8%, p = 0.036) on NWTS-4. CONCLUSIONS: Partly because of lower postrecurrence mortality among nonirradiated patients, prevention of flank recurrence by RT did not improve survival. It is important to evaluate entire treatment policies with regard to long-term outcomes.
Authors: G J D'Angio; A Evans; N Breslow; B Beckwith; H Bishop; V Farewell; W Goodwin; L Leape; N Palmer; L Sinks; W Sutow; M Tefft; J Wolff Journal: Cancer Date: 1981-05-01 Impact factor: 6.860
Authors: G J D'Angio; N Breslow; J B Beckwith; A Evans; H Baum; A deLorimier; D Fernbach; E Hrabovsky; B Jones; P Kelalis Journal: Cancer Date: 1989-07-15 Impact factor: 6.860
Authors: J Lemerle; P A Voute; M F Tournade; C Rodary; J F Delemarre; D Sarrazin; J M Burgers; B Sandstedt; H Mildenberger; M Carli Journal: J Clin Oncol Date: 1983-10 Impact factor: 44.544
Authors: M F Tournade; C Com-Nougué; P A Voûte; J Lemerle; J de Kraker; J F Delemarre; M Burgers; J L Habrand; C G Moorman; D Bürger Journal: J Clin Oncol Date: 1993-06 Impact factor: 44.544
Authors: Robert C Shamberger; James R Anderson; Norman E Breslow; Elizabeth J Perlman; J Bruce Beckwith; Michael L Ritchey; Gerald M Haase; Milton Donaldson; Paul E Grundy; Robert Weetman; Max J Coppes; Marcio Malogolowkin; Patricia D Shearer; Morris Kletzel; Patrick R M Thomas; Roger Macklis; Vicki Huff; Douglas A Weeks; Daniel M Green Journal: Ann Surg Date: 2010-03 Impact factor: 12.969
Authors: John A Kalapurakal; Sierra M Li; Norman E Breslow; J Bruce Beckwith; Michael L Ritchey; Robert C Shamberger; Gerald M Haase; Patrick R M Thomas; Paul Grundy; Daniel M Green; Giulio J D'Angio Journal: Int J Radiat Oncol Biol Phys Date: 2010-01-01 Impact factor: 7.038